Hear about target validation techniques and scalable methodologies that will allow CRISPR technology to progress efficiently.
Presented by GEN, Produced with Support from Lonza
The therapeutic potential of the genome editing system CRISPR-Cas9 has ignited the imaginations of basic science and clinical researchers. It seems that almost every day investigators are developing innovative ways to utilize the gene editing technology as an intervention for treating a vast array of diseases. As this cutting-edge science rapidly advances, it is important for researchers to have a firm grasp on appropriate target validation techniques and scalable methodologies that will allow CRISPR technology to progress efficiently.
Shondra Miller, Ph.D. Director/Assistant Member Center for Advanced Genome Engineering (CAGE), St. Jude Children’s Research Hospital
Alexander Marson, M.D., Ph.D. Assistant Professor UCSF School of Medicine
You Will Learn:
How various site-specific nuclease validation assays compare when determining the efficiency of the CRISPR-Cas9 system
Modalities for incorporating CRISPR into primary human cells, along with techniques for effective scale-up
Efficient Genome Editing using Lonza's NucleofectorTM Technology
On-site Demonstration of 4D-NucleofectorTM Technology
4D-NucleofectorTM X and Y Unit
Are you interested in seeing the NucleofectorTM Technology for medium-throughput applications in your lab and how it performs for your cells? One of our transfection specialists can come to your lab, introduce you to your preferred platform and perform a transfection experiment with your cell type of interest.